PMA P100009S028

Device
MitraClip NT Clip Delivery System and MitraClip NTR/XTR Clip Delivery System
Applicant
ABBOTT MEDICAL
PMA number
P100009
Supplement
S028
Product code
NKM
Decision date
2019-03-14
Classification
Mitral Valve Repair Devices
Generic name
Mitral valve repair devices
Approval order statement
Approval for the MitraClip NT Clip Delivery System and MitraClip NTR/XTR Clip Delivery System for expanding the indication to include secondary mitral regurgitation. The devices, when used with maximally tolerated guideline-directed medical therapy (GDMT), are indicated for the treatment of symptomatic, moderate-to-severe or severe secondary (or functional) mitral regurgitation (MR; MR >= Grade III per American Society of Echocardiography criteria) in patients with a left ventricular ejection fraction (LVEF) >= 20% and <= 50%, and a left ventricular end systolic dimension (LVESD) <= 70 mm whose symptoms and MR severity persist despite maximally tolerated GDMT as determined by a multidisciplinary heart team experienced in the evaluation and treatment of heart failure and mitral valve disease.
Summary
<a href="http://www.accessdata.fda.gov/cdrh_docs/pdf10/P100009S028B.pdf" target="_new">Summary of Safety and Effectiveness</a>

Current openFDA PMA Record#

Device
MitraClip NT Clip Delivery System and MitraClip NTR/XTR Clip Delivery System
Applicant
ABBOTT MEDICAL
PMA number
P100009
Supplement
S028
Product code
NKM
Generic name
Mitral valve repair devices
Decision date
2019-03-14
Decision code
APPR
Date received
2018-11-06
Supplement type
Panel Track
Supplement reason
Labeling Change - Indications/instructions/shelf life/tradename
Approval order statement
Approval for the MitraClip NT Clip Delivery System and MitraClip NTR/XTR Clip Delivery System for expanding the indication to include secondary mitral regurgitation. The devices, when used with maximally tolerated guideline-directed medical therapy (GDMT), are indicated for the treatment of symptomatic, moderate-to-severe or severe secondary (or functional) mitral regurgitation (MR; MR >= Grade III per American Society of Echocardiography criteria) in patients with a left ventricular ejection fraction (LVEF) >= 20% and